Strand Therapeutics operates as a biotechnology company. It offers immunotherapies to produce target cancer-killing proteins during immunotherapy. It develops a platform for messenger ribonucleic acid therapeutics that are bioengineered to enable precise control of the location, timing, intensity and duration of therapeutic activity. The company was founded in 2017 and is based in Boston, Massachusetts.